Yesterday, Eli Lilly asked the Food and Drug Administration to fast-track its new Alzheimer's drug, donanemab. According to an article published online by The Motley Fool, "Lilly is seeking the go-ahead via the controversial "accelerated approval" process, which only requires proof that it is "reasonably likely" to help." Read more about it here: fool.com/donanemab.
If approved, donanemab will only be the second drug in 18 years approved to treat Alzheimer's disease. Biogen's Aducanumab was approved this past June.
For more information about we support people living with Alzheimer's disease and other forms of dementia, contact us at 440-294-1500 (Cleveland) or 614-356-9810 (Columbus).
